La Jolla Labs employs high-throughput screening and machine learning to design and evaluate RNA therapeutics, focusing on antisense oligonucleotides for neuro-related conditions. This technology accelerates the drug discovery process by efficiently identifying potent and selective drug candidates, significantly reducing the time and cost associated with traditional development methods.
Funding
$3.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Developing effective RNA therapeutics, particularly antisense oligonucleotides (ASOs) for neurological disorders, is challenging due to the complexity of target identification and the need for precise drug candidates. Traditional drug discovery methods are often time-consuming and costly, requiring extensive manual screening and optimization.
Solution
La Jolla Labs offers an RNA-targeting discovery platform that leverages high-throughput screening and machine learning to accelerate the design and evaluation of RNA therapeutics. Their approach combines automated wet-lab screening with advanced bioinformatics to identify potent and selective ASO candidates. The platform aims to streamline the drug discovery process, reducing both the time and cost associated with developing RNA-based therapies for neuro-related conditions. Their LJSplice software provides insights into RNA binding proteins, enabling targeted splicing strategies.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing RNA therapeutics for neurological disorders.
Features
- High-throughput screening of ASO therapeutics using robotics and automation for potency and selectivity.
- Machine learning and AI techniques to build predictive oligonucleotide therapeutic tools.
- LJSplice software for designing efficient and targeted splicing strategies.